[Edaily Reporter KIM SAE-MI ] Lee Dong-hoon, President of SK BIOPHARMACEUTICALS, purchased approximately 180 million won worth of the company’s shares immediately after securing “Opacalim,” a next-generation epilepsy treatment candidate.

SK BIOPHARMACEUTICALS(326030)The company announced on the 31st that President Lee Dong-hoon purchased 2,000 shares of the company’s stock on the open market on the 27th. The average purchase price was 90,898 won per share, bringing the total purchase amount to 181.8 million won.

This stock purchase took place the day after SK BIOPHARMACEUTICALS announced the agreement to acquire Opakalim. Previously, on the 26th, SK BIOPHARMACEUTICALS signed an agreement with U.S.-based Biohaven to acquire global rights to its Kv7 potassium channel-related pipeline—including Opakalim—and its discovery platform.

Opacalim is a selective Kv7 potassium channel activator currently undergoing Phase 2/3 clinical trials in adult patients with partial seizures. SK BIOPHARMACEUTICALS aims to develop Opacalim as its next-generation global new drug candidate following “cenobamate” and launch it in the U.S. market as early as 2029.

Yoo Chang-ho, Head of Strategy at SK BIOPHARMACEUTICALS, who led the Opakalim licensing agreement, also purchased 500 shares of the company’s stock following the announcement of the deal.

An SK BIOPHARMACEUTICALS official stated, “This share repurchase demonstrates management’s commitment to the company’s mid- to long-term growth, driven by the growth momentum of cenobamate and next-generation growth engines such as opacalim.”